Porous Bead EV Sequestration for Stable Urine Sample Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating extracellular vesicles (EVs) are labor-intensive, costly, and unreliable, and they face challenges in minimizing contamination and degradation during transport or storage, particularly in urine samples, which are highly variable and prone to cell lysis during transport.
Innovation Solution
The use of non-toxic, porous beads such as diatomaceous earth (DE) for size-selective sequestration and reduction of bioparticles in biofluids, including urine, without the need for high-speed centrifugation or expensive reagents, and a device for immediate cell removal and stabilization during transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for isolating extracellular vesicles (EVs) are used, then EV isolation can be achieved, but the process is labor-intensive, costly, and unreliable
Solution Approach 1:
The patent employs porous beads with specific pore sizes to selectively sequester bioparticles through physical adsorption. The porous structure enables size-selective capture of EVs and other bioparticles from biofluids, providing a simple yet reliable isolation method that avoids complex centrifugation and chromatography procedures.
Solution Approach 2:
The invention extracts and removes bioparticles from biofluids using porous beads that selectively bind to these particles. This extraction approach simplifies the isolation process by directly capturing EVs and other bioparticles without requiring complex multi-step procedures, thereby reducing labor intensity and cost while improving reliability.
2Ease of operation
If urine samples are transported or stored without immediate processing, then sample collection is flexible, but cell lysis and contamination occur
Solution Approach 1:
The patent incorporates porous beads into urine collection devices that immediately sequester bioparticles at the time of sample collection. This preliminary action prevents cell lysis and contamination during transport and storage by continuously capturing bioparticles, thereby maintaining sample integrity while allowing flexible collection timing.
Solution Approach 2:
The porous beads act as an intermediary substance between the urine sample and the analysis process. They continuously interact with the biofluid to capture and stabilize bioparticles, serving as a protective mediator that prevents degradation and contamination during the transport and storage period.
3Measurement precision
If antibody-based methods are used for bioparticle sequestration, then specific binding can be achieved, but the method has limited capacity and requires expensive reagents
Solution Approach 1:
The patent uses porous beads with optimized pore sizes that provide both specificity and high capacity for bioparticle sequestration. The physical pore structure enables selective capture of bioparticles based on size exclusion, achieving binding specificity without requiring expensive antibodies, while simultaneously providing high sequestration capacity due to the large surface area and volume of the porous matrix.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for efficient, cost-effective isolation and stabilization of bioparticles, reducing contamination and degradation, and is suitable for various biofluids, including urine, with minimal side effects and higher capacity compared to antibody-based methods.
Implementation Method 1
contacting a biofluid of an organism with a composition that includes porous beads capable of targeted sequestration and/or reduction of bioparticles from the contacted biofluid
Implementation Method 2
non-toxic, porous beads such as diatomaceous earth (DE) for size-selective sequestration and reduction of bioparticles in biofluids
Data Source
AI summary
Compositions and methods for the application of non-toxic bioparticle (e.g., extracellular vesicle (EV)) absorbing materials (e.g., non-toxic exosome reducing materials) for prophylactic, therapeutic, validation and/or experimental purposes are provided.